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Abstract
Background: Inflammatory cytokine genes have been proposed as good candidate genes for conferring susceptibility to
diabetic nephropathy. In the present study, we examined the combined effect of multiple alleles of pro inflammatory
cytokine genes for determining the risk of nephropathy in type 2 diabetic patients.
Methodology/Principal Findings: Eight single nucleotide polymorphisms (SNPs) of pro-inflammatory cytokine genes (CCL2,
TGFB1, IL8, CCR5, and MMP9) were genotyped in two independently ascertained type 2 diabetic cohorts with (DN) and
without nephropathy (DM); consisting of patients from North India (n = 495) and South India (n = 188). Genotyping was
carried out using PCR, allele specific oligonucleotide-PCR (ASO-PCR), PCR-RFLP and TaqMan allelic discrimination assays and
the gene–gene interaction among genetic variants were determined by multi dimensional reduction (MDR) software. Serum
high sensitive CRP (hs-CRP) levels were measured by ELISA. The hs-CRP levels were significantly higher in DN as compared
to the DM group (p,0.05). The CCL2, IL8, CCR5 and MMP9 polymorphisms were found to be associated with the risk of
diabetic nephropathy. Frequency of CCL2 II, IL8 -251AA, CCR5 59029AA and MMP9 279Gln/Gln genotypes were significantly
higher in DN than in DM group (p,0.05) and associated with an increased risk of nephropathy in both North and South
Indian cohorts. CCR5 DD and IL8 -251AA genotypes were more prevalent in North Indian DN group only. The co-occurrence
of risk associated genotypes (II, -2518GG (CCL2), DD (CCR5) and 279Gln/Gln (MMP9) conferred a tenfold increased risk of
nephropathy among type 2 diabetics (p,0.0002).
Conclusion: The present study highlights that common variants of inflammatory cytokine genes exert a modest effect on
risk of DN and a combination of risk alleles confer a substantial increased risk of nephropathy in type 2 diabetes among
Asian Indians.
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Introduction
Genetic susceptibility plays an important role in the pathogen-
esis of diabetic nephropathy (DN) and multiple genetic approach-
es, including candidate gene association studies and the genome-
wide association study (GWAS) are being pursued to identify the
susceptibility gene(s) for DN [1–7]. In recent years, it has become
evident that inflammatory mechanisms contribute significantly to
the development and progression of DN. These include the
infiltration of renal compartments by lymphocytes and mono-
cytes/macrophages as well as local production of cytokines and
chemokines in the kidney [8,9]. Although the mechanisms
underlying the regulation of these cytokines in the kidneys of
patients with diabetes mellitus remain unclear, it has been
proposed that genetic variations in the genes encoding the
inflammatory cytokines might confer susceptibility to DN [10]
by altering their functions or expressions. For example, a promoter
polymorphism (-2518A/G) in the CCL2 gene was found to be
associated with progressive kidney failure in Koreans with type 2
diabetes [11] and TGFB1 T869C gene polymorphism showed
association with nephropathy in type 2 diabetic Chinese patients
[12]. Polymorphisms in the CCR5 and MMP9 have been also
reported to be associated with the increased risk of nephropathy
[5,13–15]. In a polygenic complex disorder like DN, association of
individual polymorphisms in genes may be small and sometimes
non-informative, whereas specific combinations of specific geno-
types may be more relevant. However, few studies have examined
the multiple alleles simultaneously for determining the risk of DN
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[16,17]. In the present study, we investigated combinatorial
polymorphisms among five inflammatory genes (TGFB1: T869C
(Leu10Pro) and Tyr81His; CCL2: A-2518G and Insertion/
Deletion (I/D); CCR5: Insertion/Deletion (I/D) and G59029A;
IL8: T-251A; MMP9: Arg279Gln (G.A)) for association with the
risk of susceptibility to diabetic nephropathy.
Results
Demographic and clinical characteristics of the subjects enrolled
in the study are given in Table 1. The mean duration of type 2
diabetes (considered with respect to date of detection of diabetes) was
similar in diabetic nephropathy and diabetes without nephropathy
group (DM) (16 vs.15 years). Percent frequency of retinopathy was
higher in DN (76.2%) as compared to DM (37.7%) group.
High sensitivity- C Reactive Protein (hs-CRP) levels
The mean plasma hs-CRP levels were significantly higher in
cases (2.6561.2 mg/L; p,0.05) as compared to controls
(1.8961.1 mg/L) (Table 1). hs-CRP levels were not associated
with any particular genotype within the case or control groups as
per logistic regression analysis and t-test performed (data not
shown).
Genetic Analysis (North Indian Cohort)
All the polymorphisms examined in this study were in Hardy-
Weinberg equilibrium in both set of populations. Allele and
genotype frequencies of the polymorphisms of the TGFB1, CCL2,
IL8, CCR5, and MMP9 genes are given in Table 2. The genotype
frequencies were different between DN and DM groups. Five of
the eight variant alleles showed significantly higher allele
Table 1. Demographic profile of type 2 diabetes subjects (with & without) nephropathy among North India and South India.
North Indian Cohorts
Type 2 diabetes subjects a vs b
With nephropathya (n=240) Without nephropathyb (n =255)
Age (years) 60.1266.2 58.168.0 0.32d
Males/Females (%) 94/146 (39/61) 105/150 (41/59) 1.0e
Mean duration of diabetes (years) 16.363.3 15.6265.25 .0.05d
Mean arterial S.B.P. (mmHg)* 145.4622.5 135.08617.7 ,0.001c
Mean arterial D.B.P. (mmHg)* 88.8610.2 84.2167.51 ,0.001c
BMI (Kg/m2)* 27.862.9 23.9562.95 ,0.001c
hs-CRP (mg/L) 2.6561.2 1.8961.1 ,0.01d
S. Creatinine (mg%)* 4.2262.07 1.1460.11 ,0.001d
Blood Urea (mg%)* 106.7646.2 36.2615.2 0.00d
Random blood sugar (mg/dl) 182.7653.5 181.3656.5 0.78d
Total cholesterol (130–250 mg%) 255.3664.1 259.24663.7 0.88d
Tryglycerides (mg%) 204.8639.2 207.6638.2 0.85d
HDL (mg%) 63.5615.1 61.05616.08 0.75d
Retinopathy (%)* 76.2 37.7 ,0.05e
South Indian Cohorts
With nephropathya (n=96) Without nephropathyb (n =92) a vs b
Age (years) 60.568.7 53.5612.1 0.08d
Males/Females (%) 53/43 (55/45) 47/45 (51/49) 0.97e
Mean duration of diabetes (years) 17.467 13.062.8 .0.05d
Mean arterial S.B.P. (mmHg)* 143.5620.5 127.4617.6 ,0.001c
Mean arterial D.B.P. (mmHg)* 85.1610.5 77.2612.2 ,0.001c
BMI (Kg/m2)* 24.563.7 25.864.0 0.06c
S. Creatinine (mg%)* 5.561.3 1.060.2 ,0.001d
Blood Urea (mg%)* 64618.8 22.565.8 ,0.001d
Fasting blood sugar (mg/dl) 173669 161659 0.15d
Total cholesterol (130–250 mg%) 176674 192637 0.26d
Tryglycerides (mg%) 175688 165684 0.23d
HDL (mg%) 43610 44610 0.97d
*p,0.05; Values are mean6standard deviation.
aType 2 diabetic with nephropathy.
bType 2 diabetic without nephropathy.
cMann-Whitney U test.
dStudent’s t-test.
ePearson’s Chi square test.
doi:10.1371/journal.pone.0005168.t001
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Table 2. Allele and genotype frequencies of the inflammatory gene SNPs in North and South Indians.
North Indians
Polymorphisms Allele Frequency OR(95%CI) p value
DM (2n=510) DN (2n=480)
TGFB1: rs1800470 T = 362 (0.71) T = 331 (0.69) 1.1 (0.83–1.44) 0.48
869 T.C (Leu10Pro) C= 148 (0.29) C = 149 (0.31)
TGFB1 T = 497 (0.975) T = 466 (0.97) 1.14 (0.53–2.46) 0.71
Tyr81His (T.C) C= 13 (0.025) C = 14 (0.03)
CCL2: rs1024611 A=342 (0.67) A = 317 (0.66) 1.04 (0.8–1.36) 0.74
-2518 A.G G=168 (0.33) G = 163 (0.34)
CCL2: rs3917887* I = 250 (0.49) I = 326 (0.68) 2.03 (1.57–2.63) ,0.0001
Ins./Del. (D.I) D= 260 (0.51) D = 154 (0.32)
IL8: rs4073* T = 362 (0.71) T = 302 (0.63) 1.44 (1.1–1.88) 0.006
-251 T.A A=148 (0.29) A = 178 (0.37)
CCR5: Del 32* I = 250 (0.49) I = 130 (0.27) 2.58 (1.98–3.37) ,0.0001
Ins./Del.(I.D) D= 260 (0.51) D = 350 (0.73)
CCR5: 59029 G.A* G=260 (0.51) G = 153 (0.32) 2.22 (1.71–2.87) ,0.0001
A= 250 (0.49) A = 327(0.68)
MMP9: rs17576* G=342 (0.67) G = 254 (0.53) 1.81 (1.40–2.34) ,0.0001
(Arg279Gln) G.A A=168 (0.33) A = 226 (0.47)
Polymorphisms Genotype Frequency p value
DM (n=255) DN (n=240)
TGFB1: rs1800470 TT = 144 (0.565) TT = 144 (0.60)
869 T.C (Leu10Pro) TC* = 74 (0.29) TC = 41 (0.17) 0.009
CC = 37 (0.145) CC= 55 (0.23) 0.1
TGFB1: Tyr81His (T.C) TT = 242 (0.95) TT = 226(0.94)
TC = 13 (0.05) TC = 14 (0.06) 0.71
CC = 0 (0) CC= 0 (0) -
CCL2: rs1024611 AA= 122 (0.48) AA= 94 (0.39)
-2518 A.G AG* = 97 (0.38) AG= 130(0.54) 0.003
GG= 36 (0.14) GG=16 (0.07) 0.09
CCL2: rs3917887 DD= 89 (0.35) DD= 36 (0.15)
Ins./Del. (D.I) ID* = 82 (0.32) ID = 79 (0.33) 0.0005
II* = 84 (0.33) II = 125 (0.52) ,0.0001
IL8: rs4073 TT = 130 (0.51) TT = 103(0.43)
-251 T.A TA= 107 (0.42) TA = 96 (0.40) 0.51
AA* = 18 (0.07) AA= 41 (0.17) 0.0005
CCR5: Del 32 II = 94 (0.37) II = 50 (0.21)
Ins./Del. (I.D) ID = 64 (0.25) ID = 29 (0.12) 0.57
DD* = 97 (0.38) DD= 161(0.67) ,0.0001
CCR5: 59029 G.A GG= 90 (0.35) GG=40 (0.16)
GA= 80 (0.31) GA= 75 (0.31) 0.52
AA* = 85 (0.34) AA= 125 (0.52) ,0.0001
MMP9: rs17576 GG= 122(0.48) GG=72(0.30)
(Arg 279 Gln) G.A GA* = 97 (0.38) GA= 113(0.47) 0.0007
AA* = 36 (0.14) AA= 55 (0.23) 0.0002
South Indians
Polymorphisms Allele Frequency OR(95%CI) p value
DM (2n=184) DN (2n=192)
CCL2: rs3917887* I = 92 (0.5) I = 121 (0.63) 1.7 (1.12–2.57) 0.01
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frequency (CCL2 Insertion (I): p,0.0001; IL8 -251A: p,0.007;
CCR5 Deletion (D): p,0.0001, CCR5 59029A: p,0.0001; MMP9
279Gln: p,0.0001) in DN as compared to DM group. When
genotypes were stratified according to dominant and recessive
models, after the multiple logistic regression analysis (Figure 1, and
2), five genotypes (Insertion/Insertion (II) of CCL2; AA of IL8;
Deletion/Deletion (DD) and 59029AA of CCR5; and AA of
MMP9) showed significant association with high risk of DN
(p,0.05), whereas three genotypes (Deletion/Deletion (DD) of
CCL2; Insertion/Insertion (II) of CCR5; and Arg/Arg of MMP9)
showed significant association with decreased risk of DN (p,0.05).
None of the covariates (age, sex, duration of diabetes, and blood
pressure) except blood urea and serum creatinine (p,0.05) were
found to be associated with the DN (data not shown).
Genetic analysis (South Indian cohort)
Figure 3 shows the mutant allele frequency comparison between
of north Indian and south Indian subjects. The Dominant/
Recessive models after logistic regression analysis are shown in
figures 4 and 5. No significant differences in either genotype or
allele frequencies were observed between the two groups, except
for CCR5 I/D polymorphism; minor allele frequency (MAF) was
higher in north Indians as compared to South Indians.
Power calculations. Power assuming a= 0.05 and relative
risk of 1.4 was 62%, 83%, 85% and 79% for type 2 diabetic
patients with diabetic nephropathy for IL8, CCL2, CCR5, MMP9
polymorphisms (p,0.05) among North Indian population.
Gene–gene interaction
We analyzed the presence of epistatic interactions amongst
inflammatory genes, evaluating the possible (one-to-four way)
SNP combinations using the multiple dimensionality reduction
approach (MDR). All the four models (one, two, three & four
locus) had a prediction accuracy of .63% and showed
significant interactions (p,0.05), as determined empirically by
permutation testing. Four loci SNP combination of -2518AG
(CCL2), II/ID (CCL2 I/D), 279Gln/Arg (MMP9), and DD (CCR5
I/D) genotypes was found to be the best model for DN risk
prediction (accuracy 0.764; p = 0.0001, Figure 6). The predicted
odds ratio of this model was 10.6 (95% CI: 6.6–17.0). The two
loci model comprising II genotype (CCL2) and DD genotype
(CCR5) and three loci combination comprising of II (CCL2 I/D),
DD (CCR5 I/D), and -2518AG (CCL2) were also significantly
associated with three and five folds risk of DN (p = 0.0001;
p,0.02).
Discussion
Recent studies suggest inflammation to be an essential
component of type 2 DM and its complications. We measured
hs-CRP as a marker of inflammation in our diabetic cohort and
found its levels to be significantly higher in diabetic patients as
compared to controls and in nephropathy group as compared to
diabetic subjects without nephropathy indicating inflammation to
be a relevant factor in the pathogenesis of DN. Our results are
South Indians
Polymorphisms Allele Frequency OR(95%CI) p value
DM (2n=184) DN (2n=192)
Ins./Del. (D.I) D= 92 (0.5) D = 71 (0.37)
IL8: rs4073 T = 134 (0.73) T = 123 (0.64) 1.5 (0.96–2.33) 0.06
-251 T.A A= 50 (0.27) A = 69 (0.36)
CCR5: Del 32 I = 151 (0.82) I = 161 (0.84) 0.88 (0.51–1.5) 0.64
Ins./Del.(I.D) D= 33 (0.18) D = 31 (0.16)
CCR5: 59029 G.A* G=99 (0.54) G = 67 (0.35) 2.17 (1.43–3.29) 0.0002
A= 85 (0.46) A = 125 (0.65)
MMP9: rs17576* G=116 (0.63) G = 84 (0.44) 2.19 (2.45–3.31) 0.0001
(Arg 279 Gln) G.A A= 68 (0.37) A = 108 (0.56)
Polymorphisms Genotype Frequency p value
DM (n=92) DN (n=96)
CCL2: rs3917887 DD=29 (0.32) DD= 20 (0.21)
Ins./Del. (D.I) ID = 34 (0.36) ID = 32 (0.33) 0.41
II* = 29 (0.32) II = 44 (0.46) 0.03
IL8: rs4073 TT= 58 (0.63) TT = 36 (0.38)
-251 T.A TA* = 19 (0.21) TA = 51 (0.53) ,0.0001
AA=15 (0.16) AA= 9 (0.09) 0.92
CCR5: Del 32 II = 64 (0.69) II = 69 (0.72)
Ins./Del. (I.D) ID = 23 (0.26) ID = 23 (0.24) 0.82
DD=5 (0.05) DD= 4 (0.04) 0.73
CCR5: 59029 G.A GG= 35 (0.38) GG= 20 (0.21)
GA= 30 (0.33) GA= 28 (0.29) 0.26
AA* = 27 (0.29) AA= 48 (0.50) 0.003
MMP9: rs17576 GG= 42 (0.46) GG= 28 (0.29)
(Arg 279 Gln) G.A GA=31 (0.34) GA= 29 (0.30) 0.34
AA* = 19 (0.20) AA= 39 (0.41) 0.002
*p,0.05; Genotype frequency calculation is with respect to the homozygous wild type genotypes in each group.
doi:10.1371/journal.pone.0005168.t002
Table 2. Cont.
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consistent with an earlier study which has also reported increased
hs-CRP levels in diabetics with proteinuria [18].
Different inflammatory molecules, including pro-inflammatory
cytokines have been proposed as critical factors in the develop-
ment of microvascular diabetic complications, including nephrop-
athy [19]. It has been suggested that genetic variations in the genes
encoding the inflammatory cytokines might confer susceptibility to
DN by altering the function and/or expression of these cytokines.
We investigated the association of genetic polymorphism(s) in
inflammatory genes with the risk of diabetic nephropathy and
whether co-occurrence of risk conferring variants of inflammatory
genes were associated with increased risk of diabetic nephropathy
in Asian Indian type 2 diabetic subjects. The key finding of our
study was that polymorphisms in IL8, CCL2, CCR5, and MMP9
genes were associated with increased risk of nephropathy in Asian
Indian type 2 diabetics and co-occurrence of specific risk
genotypes of these genes conferred several fold greater risk of
diabetic nephropathy.
We examined eight variants of five pro-inflammatory cytokine
genes which have been either shown to be linked with DN in other
ethnic populations or were functional variants affecting expression
or function of these genes. All the examined genotypes/alleles
were in Hardy-Weinberg Equilibrium in both DN and DM
groups. We observed that specific genotypes of all the genes except
TGFB1, showed independent association with risk of DN.
CCL2, also known as Monocyte chemo-attractant protein-1
(MCP-1), is the strongest known chemo-tactic factor for monocytes
and is upregulated in DN. Recent studies suggest that this cytokine
is involved in the pathogenesis of diabetic nephropathy [20]. We
examined two polymorphisms, CCL2 A-2518G and CCL2
Insertion/Deletion in CCL2 gene for association with DN.
CCL2 -2518AG and CCL2 II genotypes showed two fold higher
risk of DN as compared to DM group. The -2518A allele (CCL2)
was reported to be associated with kidney failure in Korean type 2
DM patients. This SNP has been shown to influence CCL2
transcriptional activity, with increased CCL2 protein expression in
GG/AG genotype carriers as compared to AA carriers in response
to IL1B [13,21]. The CCL2 I/D polymorphism has been recently
reported to be associated with development of inflammatory
myopathies [22]. This is the first report of this variant being
examined for association with type 2diabetes or nephropathy
among Asian Indians.
A common 32-bp deletion mutation (CCR5 del 32) and a
promoter polymorphism CCR5 59029 (G/A) of the CCR5 gene
have recently been reported to be associated with the increased
risk of nephropathy in type 1 [21] and type 2 diabetic subjects
[15]. We too observed a significant association of CCR5 59029AA
variants with increased risk of DN in our North Indian cohort.
Our results are in conformity with other available reports of
association of this marker with DN among Asian Indians [6] and
Japanese population [14,15] and suggest that the CCR5 59029 A
allele may be an independent risk factor for diabetic nephropathy
in patients with type 2 diabetes. CCR5 59029A-genotype has been
shown to be associated with increased CCR5 expression by
peripheral blood mononuclear cells has been seen in individuals
with the [23], thereby suggesting that the genotype could regulate
CCR5 gene expression. We found CCR5 D allele to be associated
with increased risk of DN in our North Indian cohort. Limited
literature exists regarding the role of this polymorphism in diseases
other than AIDS. Male carriers of the 32-bp deletion have been
found to be at significantly higher risk of diabetic nephropathy
than non-carriers in type 1 diabetes [21]. This deletion alters the
open reading frame of the gene resulting in a truncated protein
[24]. Thus, a genetically determined impairment in the function of
the chemokine receptor CCR5 may change the profile of recruited
cells, and this may promote, for example, renal fibrosis instead of
normal tissue repair [25].
Figure 2. Multivariate logistic regression analysis in type 2
diabetic patients with TGFB1 869 (T.C), CCL2 -2518 (A.G), CCL2
(Del. Ins.), IL8 -251 (T.A), CCR5 Del 32 (Ins. Del.), and MMP9
Arg279Gln (G.A) polymorphisms as independent and diabetic
nephropathy as a dependent variable among North Indian
Cohort. *p,0.05.
doi:10.1371/journal.pone.0005168.g002
Figure 1. Univariate logistic regression analysis in type 2
diabetic patients with TGFB1 869 (T.C), CCL2 -2518 (A.G), CCL2
(Del. Ins.), IL8 -251 (T.A), CCR5 Del 32 (Ins. Del.), and MMP9
Arg279Gln (G.A) polymorphisms as independent and diabetic
nephropathy as a dependent variable among North Indian
Cohort. *p,0.05.
doi:10.1371/journal.pone.0005168.g001
Cytokine Gene Variants in DN
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We found -251AA genotype (IL8) to be associated with higher
risk of DN. The IL8 T-251A variant lies in the regulatory region
and increases the gene expression [26], suggesting that this
genotype could regulate IL8 gene expression. Increased urinary
excretion of IL8 has been reported in DN patients [27]. This
variant has been associated with inflammatory renal injury [28].
Ours is the first study showing an association of this allele with
increased risk of diabetic nephropathy.
The MMP9 Arg279Gln polymorphism lies in the substrate
binding region and decreases binding affinity of type IV collagen
to MMP9 [29]. MMP9 279Gln/Gln genotypes was found to be
associated with increased risk of DN suggesting that decreased
affinity of type IV collagen to MMP9 may lead to decreased
degradation leading to over-accumulation of such extracellular
matrix (ECM) proteins and contributing to renal damage [30].
However, further studies are required to confirm the functional
impact of this variant on diabetic nephropathy.
TGFB1 Tyr81His polymorphism is a functional SNP in the
Exon 2 of TGFB1 gene and has been previously studied in Asian
Indians with chronic renal insufficiency (6). This SNP was found to
Figure 3. Genotype frequency comparison between Asian type 2 diabetic North Indians (ANI), and South Indians (ASI) with (DN)
and without nephropathy (DM) for the four inflammatory variants. *p,0.05 Asian North Indians (ANI) vs. Asian South Indians (ASI). DM:
Diabetes without nephropathy; DN: Diabetes with nephropathy.
doi:10.1371/journal.pone.0005168.g003
Figure 4. Univariate logistic regression analysis in type 2
diabetic patients with TGFB1 869 (T.C), CCL2 -2518 (A.G), CCL2
(Del. Ins.), IL8 -251 (T.A), CCR5 Del 32 (Ins. Del.), and MMP9
Arg279Gln (G.A) polymorphisms as independent and diabetic
nephropathy as a dependent variable among South Indian
Cohort. *p,0.05.
doi:10.1371/journal.pone.0005168.g004
Figure 5. Multivariate logistic regression analysis in type 2
diabetic patients with TGFB1 869 (T.C), CCL2 -2518 (A.G), CCL2
(Del. Ins.), IL8 -251 (T.A), CCR5 Del 32 (Ins. Del.), and MMP9
Arg279Gln (G.A) polymorphisms as independent and diabetic
nephropathy as a dependent variable among South Indian
Cohort. *p,0.05.
doi:10.1371/journal.pone.0005168.g005
Cytokine Gene Variants in DN
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be monomorphic in our population and was further not analysed.
The minor allele frequency (MAF) of the second TGFB1 SNP
T869C (Leu10Pro) was similar in cases and controls (p.0.05).
Similar results have been reported in Japanese [31] and
Caucasians [32] where, no association between this SNP and
DN was observed. However, Wong et al. [33] found 869CC
genotype to be associated with DN in Chinese diabetic subjects.
The observed heterogeneity in these results could be due to ethnic
differences in these studies.
None of the polymorphisms in our study showed any association
with hs-CRP levels. A lack of association between IL6 G-174C or
IL1 RA genotypes and significant association between CRP and
diabetic nephropathy has been reported earlier too, indicating that
elevated CRP levels are associated with diabetic nephropathy
independent of polymorphisms in cytokine genes [34].
We replicated genotypic associations seen in our cohort in an
independently recruited set of diabetic patients from Southern
India. We observed that the MAF of the four of risk conferring SNPs
(CCL2 ID, CCR5 G59029A, MMP9 Arg279Gln, and IL8 T-251A)
were similar in North and South Indian populations and were
associated with increased risk of DN. However, the ‘D’ allele
frequency (CCR5 I/D polymorphism) was higher in North Indian
DN group as compared to the South Indian DN group, and did not
show association with the risk of nephropathy in the latter. These
differences may be because of the ethnic variation between the
North and South Indian populations [35,36] and/or comparatively
small sample size of South Indian subjects in our cohort. However,
the replication of our data in two independent sets of populations
suggests that these associations might be significant.
We analyzed the interaction of the individual genotypes for
conferring nephropathy risk using multifactor dimensionality
reduction (MDR) software. MDR method was developed by
Hahn et al [37] for collapsing high-dimensional genetic data into a
single dimension thus permitting interactions to be detected in
relatively small sample sizes. It identifies combinations of multi-
locus genotypes and discrete environmental factors (non-linear
interactions) that are associated with a particular disease. It
calculates the testing accuracy/Prediction error after taking into
account the number of samples. It has been used in several other
similar studies [38]. We observed significant epistatic interactions
between CCL2, CCR5 and MMP9 gene SNPs. A four loci
combination of genotypes: [-2518AG (CCL2)+II/ID (CCL2 I/
D)+279Arg/Gln (MMP9)+DD (CCR5 I/D)] was associated with
ten fold increased risk of DN as compared to the risk conferred by
individual genotypes, suggesting a synergistic interaction between
these genes towards disease susceptibility.
A relatively small sample size such as ours may be a limitation
for genetic studies; however, few investigators (mostly multi-
centric) have access to larger sample sizes. The strength of our
study is that we had an ethnically homogenous and well
phenotyped diabetic subjects enrolled from a single centre,
thereby reducing phenotyping errors and bias. The inclusion
criterion of absence of microalbuminuria on two or more
occasions for the control group ensured a good selection of
control diabetic group for the study. Also, in accordance with the
suggestions of Hattersley and McCarthy [39], the present study
fulfils most of the prerequisites for a good genetic association study.
Further, most of the variants showing positive association had a
minimum power of 76%, which has been shown to be adequate
for association studies [40,41].
In summary, our study provides evidence of the individual risk
associated with the inflammatory gene variants and also emphasizes
on the combinatorial effect of alleles of the CCL2 (I allele of I/D
polymorphism), CCR5 (D allele of I/D polymorphism) and MMP9
(279Gln allele of Arg279Gln) genes for diabetic nephropathy,
considering the epistatic effects of individual genes, while investigating
susceptibility genes in complex diseases like DN among Asian Indians.
Materials and Methods
Subject Selection
Two independently recruited groups of Type 2 diabetes
(T2DM) patients and control subjects were evaluated. The first
group consisted of unrelated 255 individuals with T2DM and no
nephropathy (DM) and 240 consecutive diabetic nephropathy
patients (DN), from North India, attending outpatient diabetes and
nephrology clinics at Post Graduate Institute of Medical Education
Figure 6. Gene–Gene interaction: Comparison between the number of interacting locus/loci and the odds ratio (relative risk)
pertaining to each SNP combination. Testing Accuracy for different combinations: single locus, 63.7 %; two locus, 65.1%; three locus, 70.7%; four
locus, 76.4%.
doi:10.1371/journal.pone.0005168.g006
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and research (PGIMER), Chandigarh, India. Replication studies
were performed on a population of 92 cases with T2DM without
nephropathy and 96 DN patients recruited from Madras Diabetes
Research foundation (MDRF), Chennai, South India enrolled in
Chennai Urban Rural Epidemiology Study (CURES) [32]. An
informed written consent was taken from all the subjects
participating in this study.
Type 2 diabetes was diagnosed on the basis of the WHO
criteria. The patients were divided into subgroups: type 2 diabetes
patients who had the disease for at least 10 years but remained free
of nephropathy (DM) and patients with nephropathy (DN).
Diabetic nephropathy status was determined on the basis of a
questionnaire, clinical features and laboratory data. Type 2
diabetic subjects diagnosed with either of the following: a) Urinary
albumin .300 mg/L or, b) an albumin:creatinine ratio .300 mg/
mg without any clinical or laboratory evidence of other kidney
disease, formed the diabetic nephropathy group. Type 2 diabetes
subjects with duration of onset of 10 years or more and negative
for urinary protein (proteinuria) and urinary albumin levels
,30 mg/L (measured on two consecutive occasions) formed
DM group. It was ensured that the diabetic nephropathy subjects
had no microscopic hematuria. In addition, the diabetic subjects
(without proteinuria) on anti-hypertensive drug treatment were
excluded from the study group in order to avoid misclassification
of phenotype. All the subjects in both groups were age, & ethnicity
matched. The research carried out was in compliance with the
Helsinki Declaration.
Ethics Statement
The study was approved by the Ethics committee of Post
Graduate Institute of Medical Education and Research, Chandi-
garh, India and also by the Ethics committee of Madras Diabetes
Research Foundation, Chennai, India.
SNP Selection and Genotyping Analysis
The genomic DNA was isolated from peripheral blood, using
the Proteinase K-chloroform-phenol method. A total of 8 SNPs of
five candidate genes (TGFB1, CCL2, CCR5, IL8, and MMP9) were
selected for the present study, SNPs were chosen based either on
Table 3. Standard PCR conditions used in genotyping the inflammatory gene variants.
SNP (rs#) Gene Primers
Amplicon
(bp)
Annealing temp.
(uC)/[MgCl2] (mmol)
Restriction
Enz./Allele size
869T.C (Leu10Pro)
(rs1800470)
P1: 59-TTC AAG ACC ACC CAC CTT CT-39 443 68.2/1.5 Msp A1I (NEB)
TGFB1 P2: 59-TCG CGG GTG CTG TTG TAC A-39 T = 285, 67, 50, 41 bp
Exon 1 C=273, 67, 50, 41, 12 bp
Tyr81His (T.C) P1: 59-CCA GAT CCT GTC CAA GCT G-39 198 57.9/2.5 Rsa I (NEB)
TGFB1 P2: 59-TGG GTT TCC ACC ATT AGC AC-39 T = 109, 89 bp
Exon 2 C=198 bp
-2518 A.G P1: 59-TCT CTC ACG CCA GCA CTG ACC-39 234 59.4/3.0 Pvu II (NEB)
(rs1024611) P2: 59-GAG TGT TCA CAT AGG CTT CTG-39 G= 159, 75 bp
CCL2 A=234 bp
Promoter
Ins./Del. P1: 59-GCT GAT CTT CCC TGG TGC TGA T-39 202/188 61.3/3.0 I = 202 bp
(rs3917887) P2: 59- CAT TAA ATC CCA GTG CTT CTG CCT A -39 D= 188 bp
CCL2
Intron 1
Del 32 P1: 59-GAA GTT CCT CAT TAC ACC TGC AGC TCT C-39 174/142 63.5/3.5 I = 174 bp
CCR5 P2: 59- CTT CTT CTC ATT TCG ACA CCG AAG CAG AG-39 D= 142 bp
Promoter
59029 G.A P1: 59-CAG TCA ACC TGG GCA AAG CC-39 453 56.5/2.5 Bst 1286I (NEB)
CCR5 P2: 59-AGC TTT GGT CCT GAG AGT CC-39 G= 408, 45 bp
A=453 bp
Promoter
-251 T.A P1: 59(1A)-CTA GAA ATA AAA AAG CAT ACA A -39 240/250 53.8/3.0 A = 240 bp
(rs4073) P2: 59(2T)-ATA AAG TTA TCT AGA AAT AAA AAA GCA TAT AT-39 T = 250 bp
IL8 P3: 59-TAG AGA ACT TAT GCA CCC TCA-39
Promoter
Arg279Gln G.A P1: CTCCTCGCCCCAGGACTCT - - TaqMan assay
(rs17576) ACACCC[A/G]GGACGGCAATGC
MMP9 TGATGGGAAACCC
Exon 6
*The primers for these SNPs have been designed using Primer 3 software.
doi:10.1371/journal.pone.0005168.t003
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their location or functional nature (promoter or exonic) or on their
widely analyzed status. Details including location of SNPs in their
respective genes, primer sequences, PCR conditions and restric-
tion enzyme with product sizes are given in Table 3. The digested
PCR products were run on 12% polyacrylamide gel followed by
silver staining.
One SNP, MMP9 Gly279Arg was genotyped using the TaqMan
allelic discrimination Assay, using the Applied Biosystems 7300
Real-Time PCR System, USA. Two reporter dyes VIC and FAM
were used to label the Allele 1 and 2 probes and a 59 Nuclease
Assay was carried out. Fluorescence was then measured followed
by automatic allele calling.
Biochemical Investigations
Serum creatinine, blood urea, triglycerides, HDL, total
cholesterol, and blood glucose levels were measured using their
respective kits; high sensitive C Reactive Protein (hs-CRP) was
assayed using Enzyme Linked Immuno-Sorbent Assay (ELISA)
(Calbiotech Inc., USA) as per instructions of the manufacturer.
Statistical analysis
The statistical tests were performed, using the Statistical
package for Social Sciences (SPSS Inc., Chicago, IL, USA) version
13.0. Discrete and continuous variables were compared between
various groups using Pearson’s x2 test and unpaired t-test as
appropriate. Parameters showing skewed distribution (diastolic
and systolic blood pressure, and serum creatinine) were compared
using Mann-Whitney U test. Pearson’s x2 test (362 contingency
table) was used to assess association of SNPs with renal disease
between the diabetic nephropathy group (cases) and diabetes
without nephropathy group (controls). Significant allelic and
genotypic associations calculated by Pearson’s x2 test were used
for evaluating odds ratio (O.R.) and 95% confidence intervals (CI)
as well. The genotypes at their respective loci were coded as
recessive (e.g., TGFB1 869TT vs. 869TC+CC) and as dominant
models (e.g., TGFB1 869CC vs. TC+TT). The seven polymor-
phisms were then assessed for relation by univariate logistic
regression analysis and further the variables showing a statistically
significant association were made to undergo multivariate
regression analysis. Power of the sample size (subjects) was
calculated using the Power for Association with Errors (PAWE)
software (http://linkage.rockefeller.edu/pawe) [42,43]. Hardy
Weinberg Equilibrium was calculated as performed previously
[44]. We evaluated the gene–gene interactions (intra and inter)
among the large number of loci in our study using the multiple
dimensionality reduction (MDR) method (http://www.epistasis.
org/open-source-mdrproject.html).
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